Ditropan XL

See also: Generic Ditropan

Ditropan XL is a brand name of oxybutynin, approved by the FDA in the following formulation(s):

DITROPAN XL (oxybutynin chloride - tablet, extended release; oral)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: December 16, 1998
  
  Strength(s): 10MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: June 22, 1999
  
  Strength(s): 15MG ^[RLD][AB]

Has a generic version of Ditropan XL been approved?

A generic version of Ditropan XL has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ditropan XL and have been approved by the FDA:

oxybutynin chloride tablet, extended release; oral

• 
  Manufacturer: IMPAX PHARMS
  
  Approval date: November 9, 2006
  
  Strength(s): 15MG ^[AB]


• 
  Manufacturer: IMPAX PHARMS
  
  Approval date: May 9, 2007
  
  Strength(s): 10MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: November 9, 2006
  
  Strength(s): 10MG ^[AB], 5MG ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: May 10, 2007
  
  Strength(s): 15MG ^[AB]


• 
  Manufacturer: OSMOTICA PHARM
  
  Approval date: February 4, 2009
  
  Strength(s): 10MG ^[AB], 15MG ^[AB], 5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ditropan XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Dosage form comprising oxybutynin
  Patent 5,674,895
  Issued: October 7, 1997
  Inventor(s): Guittard; George V. & Jao; Francisco & Marks; Susan M. & Kidney; David J. & Gumucio; Fernando
  Assignee(s): Alza Corporation
  A composition comprising oxybutynin and a device comprising oxybutynin are disclosed for oxybutynin therapy.
  
  Patent expiration dates:
  
  
  • May 22, 2015
    
  
  
  
  • November 22, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Dosage form comprising oxybutynin
  Patent 5,840,754
  Issued: November 24, 1998
  Inventor(s): Guittard; George V. & Jao; Francisco & Marks; Susan M. & Kidney; David J. & Gumucio; Fernando
  Assignee(s): ALZA Corporation
  A composition comprising oxybutynin, a device comprising oxybutynin, and a method for administering oxybutynin are disclosed for oxybutynin therapy.
  
  Patent expiration dates:
  
  
  • May 22, 2015
    
  
  
  
  • November 22, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Dosage form and method for treating incontinence
  Patent 5,912,268
  Issued: June 15, 1999
  Inventor(s): Guittard; George V. & Jao; Francisco & Marks; Susan M. & Kidney; David J. & Gumucio; Fernando E.
  Assignee(s): Alza Corporation
  A composition comprising oxybutynin, a device comprising oxybutynin, and a method for administering oxybutynin are disclosed for oxybutynin therapy.
  
  Patent expiration dates:
  
  
  • May 22, 2015
    
  
  
  
  • November 22, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for the management of incontinence
  Patent 6,262,115
  Issued: July 17, 2001
  Inventor(s): Guittard; George V. & Jao; Francisco & Marks; Susan M. & Kidney; David J. & Gumucio; Fernando E.
  Assignee(s): ALZA Coporation
  A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone, and for other therapy.
  
  Patent expiration dates:
  
  
  • May 22, 2015
    
    ✓ 
    Patent use: MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
  
  
  
  • November 22, 2015
    
    ✓ 
    Patent use: MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Ditropan XL Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Ditropan XL Consumer Information (Cerner Multum)
• Ditropan XL Advanced Consumer Information (Micromedex)
• Oxybutynin Consumer Information (Drugs.com)
• Oxybutynin Consumer Information (Wolters Kluwer)
• Oxybutynin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Oxybutynin Gel Consumer Information (Wolters Kluwer)
• Oxybutynin Syrup Consumer Information (Wolters Kluwer)
• Oxybutynin System Consumer Information (Wolters Kluwer)
• Oxybutynin Consumer Information (Cerner Multum)
• Oxybutynin topical Consumer Information (Cerner Multum)
• Oxybutynin transdermal Consumer Information (Cerner Multum)
• Oxybutynin Advanced Consumer Information (Micromedex)
• Oxybutynin Transdermal Advanced Consumer Information (Micromedex)
• Oxybutynin Chloride AHFS DI Monographs (ASHP)